Cargando…

The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre

BACKGROUND: Approximately 10% of patients with osteoarthritis (OA) of the knee have unicompartmental OA confined to the patellofemoral joint (PFJ). The main surgical options are total knee replacement (TKR) and PFJ replacement (PFJR). PFJR has a number of advantages over TKR, including being less in...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhbari, Pouya, Malak, Tamer, Dawson-Bowling, Sebastian, East, Debra, Miles, Kim, Butler-Manuel, P. Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Orthopaedic Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515456/
https://www.ncbi.nlm.nih.gov/pubmed/26217462
http://dx.doi.org/10.4055/cios.2015.7.2.171
_version_ 1782382905912197120
author Akhbari, Pouya
Malak, Tamer
Dawson-Bowling, Sebastian
East, Debra
Miles, Kim
Butler-Manuel, P. Adrian
author_facet Akhbari, Pouya
Malak, Tamer
Dawson-Bowling, Sebastian
East, Debra
Miles, Kim
Butler-Manuel, P. Adrian
author_sort Akhbari, Pouya
collection PubMed
description BACKGROUND: Approximately 10% of patients with osteoarthritis (OA) of the knee have unicompartmental OA confined to the patellofemoral joint (PFJ). The main surgical options are total knee replacement (TKR) and PFJ replacement (PFJR). PFJR has a number of advantages over TKR, including being less invasive, preserving the unaffected parts of the knee, allowing faster recovery and better range of motion and function. We report our prospective mid-term results of the Avon PFJR for established isolated PFJ arthritis in 61 consecutive procedures. METHODS: Sixty-one Avon PFJRs were performed in 57 patients. The outcome measures were the new Oxford knee score (OKS), Hungerford and Kenna score (HKS), and Crosby Insall knee scores. Only patients with severe isolated PFJ OA were included. The diagnosis was based on a combination of clinical, radiological and, where available, arthroscopic findings. RESULTS: Mean follow-up was 5.09 years (range, 12 to 124 years). There were 2 revisions in the first 5 years. The median HKS score was 80 (interquartile range, 70 to 95) and the mean OKS was 31.8 (± standard deviation, 8.7) at 5 years. These were significantly better (p < 0.001) than the preoperative scores. CONCLUSIONS: The Avon prosthesis gives good functional outcomes in the medium term and survives well. Our data support other studies in the literature and is the largest independent prospective study to date.
format Online
Article
Text
id pubmed-4515456
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Orthopaedic Association
record_format MEDLINE/PubMed
spelling pubmed-45154562015-07-27 The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre Akhbari, Pouya Malak, Tamer Dawson-Bowling, Sebastian East, Debra Miles, Kim Butler-Manuel, P. Adrian Clin Orthop Surg Original Article BACKGROUND: Approximately 10% of patients with osteoarthritis (OA) of the knee have unicompartmental OA confined to the patellofemoral joint (PFJ). The main surgical options are total knee replacement (TKR) and PFJ replacement (PFJR). PFJR has a number of advantages over TKR, including being less invasive, preserving the unaffected parts of the knee, allowing faster recovery and better range of motion and function. We report our prospective mid-term results of the Avon PFJR for established isolated PFJ arthritis in 61 consecutive procedures. METHODS: Sixty-one Avon PFJRs were performed in 57 patients. The outcome measures were the new Oxford knee score (OKS), Hungerford and Kenna score (HKS), and Crosby Insall knee scores. Only patients with severe isolated PFJ OA were included. The diagnosis was based on a combination of clinical, radiological and, where available, arthroscopic findings. RESULTS: Mean follow-up was 5.09 years (range, 12 to 124 years). There were 2 revisions in the first 5 years. The median HKS score was 80 (interquartile range, 70 to 95) and the mean OKS was 31.8 (± standard deviation, 8.7) at 5 years. These were significantly better (p < 0.001) than the preoperative scores. CONCLUSIONS: The Avon prosthesis gives good functional outcomes in the medium term and survives well. Our data support other studies in the literature and is the largest independent prospective study to date. The Korean Orthopaedic Association 2015-06 2015-05-18 /pmc/articles/PMC4515456/ /pubmed/26217462 http://dx.doi.org/10.4055/cios.2015.7.2.171 Text en Copyright © 2015 by The Korean Orthopaedic Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Akhbari, Pouya
Malak, Tamer
Dawson-Bowling, Sebastian
East, Debra
Miles, Kim
Butler-Manuel, P. Adrian
The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title_full The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title_fullStr The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title_full_unstemmed The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title_short The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre
title_sort avon patellofemoral joint replacement: mid-term prospective results from an independent centre
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515456/
https://www.ncbi.nlm.nih.gov/pubmed/26217462
http://dx.doi.org/10.4055/cios.2015.7.2.171
work_keys_str_mv AT akhbaripouya theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT malaktamer theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT dawsonbowlingsebastian theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT eastdebra theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT mileskim theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT butlermanuelpadrian theavonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT akhbaripouya avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT malaktamer avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT dawsonbowlingsebastian avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT eastdebra avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT mileskim avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre
AT butlermanuelpadrian avonpatellofemoraljointreplacementmidtermprospectiveresultsfromanindependentcentre